NCT05442658

Importance and Association of Gut Microbiota and Biochemical Metabolites on Children Allergic Disorder

Completed Last updated 5 July 2022

What this trial tests

trial testing Microbiota in Allergic Disorder in 120 participants. Completed in 31 July 2019.

Timeline

1 August 2016

Primary endpoint
31 July 2019

31 July 2019

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 August 2016
Primary completion	31 July 2019
Estimated completion	31 July 2019

Drugs / interventions tested

• Microbiota

Conditions studied

• Allergic Disorder — all drugs for Allergic Disorder →
• Food Hypersensitivity — all drugs for Food Hypersensitivity →
• Food Allergy in Children — all drugs for Food Allergy in Children →

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 6 Months to 6, any sex, with Allergic Disorder or Food Hypersensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Food allergies account for only a small percentage of all adverse reactions to foods and their prevalence has increased over the past 10-15 years, particularly in industrialized countries: 3-6% of children under 3 years of age and 1-3% of adults. Food allergens in children are represented by milk, egg, wheat, soy, peanuts, tree nuts, fish, and shellfish. The majority of allergic processes that develop during the childhood tend to abate with age, whereas those that occur during adulthood tend to persist. Hypersensitivity refers to an excessive immunological reaction to food antigens with undesirable consequences.

The first aim of our study is to evaluate the role of intestinal microbiota and their relationship with immune tolerance or allergic disorder. The second aim of our study is determining the biochemical metabolites on the host (human being) in allergic disorder, and these biochemical metabolites can be measured in fecal or urine samples by metabolomics methods. We try to seek to gain an advanced understanding of gut microbiota and biochemical metabolites associated with mucosal immune responses in the host. These findings could be useful for developing strategies to modify the gut microbiota or medical applications (e.g. healthy microbe preparations) involving beneficial microorganisms to control the development of allergic disorders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.